BACLOFEN | N215602 | AZURITY PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AZURITY PHARMACEUTICALS, INC. v. MSN PHARMACEUTICALS INC, et al 2 patentsANDA 220553Baclofen | D.N.J. | 2025-07-25 | Terminated 2025-11-13 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$5.98
per ml
Lowest NADAC/Unit
$3.61
per ml
Brand NDCs
1
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52652600101FLEQSUVY 25 MG/5 ML SUSPENSION | $5.98 | ML | Brand | $3.61 | 2026-10-21 |
| 52536060012BACLOFEN 25 MG/5 ML SUSPENSION | $3.79 | ML | Generic | — | 2026-10-21 |
| 52536060011BACLOFEN 25 MG/5 ML SUSPENSION | $3.61 | ML | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.